Generated Narrative: StructureDefinition bcr-cancer-registration-form Name Flags Card. Type Description & Constraints <a href="StructureDefinition-bcr-cancer-registration-form-definitions.html#bcr-cancer-registration-form" title="Logical model of the Belgian standard cancer registration form#xA;(*Kankerregistratieformulier voor een nieuwe diagnose*).#xA;This is what hospitals submit to the Belgian Cancer Registry through WBCR#xA;or via batch extraction for every new cancer diagnosis.#xA;#xA;Distinct from `BCRCancerCase`, which models the *published research dataset*#xA;derived from these submissions plus registry follow-up.#xA;#xA;Source (canonical): Bijlage 55 to the RIZIV Verordening of 28 July 2003,#xA;as amended by the Verordening of 15 December 2025 (Belgisch Staatsblad#xA;23-12-2025, p. 96356).">bcr-cancer-registration-form 0..* Base BCR Cancer Registration Form — Bijlage 55 (Logical Model) #xD; patientName 1..1 string Patient name #xD; birthDate 1..1 date Date of birth #xD; nationalOrInsuranceNumber 1..1 string INSZ / Ziekenfondsnummer #xD; sex 1..1 code Sex Binding: BCR Sex at Birth (required) #xD; incidenceDate 1..1 date Incidence date #xD; <a href="StructureDefinition-bcr-cancer-registration-form-definitions.html#bcr-cancer-registration-form.basisOfDiagnosis" title="Most reliable method by which the diagnosis was established. Codes:#xA;2 = histology of primary tumour, 3 = histology of metastasis,#xA;4 = cytology / haematology, 5 = technical investigation (RX, endoscopy, …),#xA;6 = clinical, 7 = tumour marker (PSA, hCG, AFP, Ig, …),#xA;8 = cytogenetic / molecular tests, 9 = unknown.">basisOfDiagnosis 1..1 code Basis for diagnosis Binding: BCR Basis of Diagnosis (required) #xD; <a href="StructureDefinition-bcr-cancer-registration-form-definitions.html#bcr-cancer-registration-form.whoPerformanceScore" title="Score at incidence date. Codes:#xA;0 = asymptomatic, normal activity; 1 = symptomatic but ambulatory;#xA;2 = symptomatic, bedridden <50% per day; 3 = symptomatic, bedridden >50% per day;#xA;4 = fully dependent, 100% bedridden.">whoPerformanceScore 0..1 code WHO performance score at diagnosis Binding: BCR WHO Performance Score (required) #xD; primaryTumourLocation 1..1 code Primary tumour localisation Binding: BCR ICD-O-3 Topography (extensible) #xD; laterality 0..1 code Laterality Binding: BCR Laterality (required) #xD; histologyMorphology 1..1 code Histology — morphology Binding: BCR ICD-O-3 Morphology (extensible) #xD; histologyBehaviour 1..1 code Histology — behaviour Binding: BCR ICD-O-3 Behaviour (digit only) (required) #xD; differentiationGrade 0..1 code Differentiation grade Binding: BCR Differentiation Grade (required) #xD; clinicalT 0..1 string Clinical T (cT) #xD; clinicalN 0..1 string Clinical N (cN) #xD; clinicalM 0..1 string Clinical M (cM) #xD; pathologicalT 0..1 string Pathological T (pT) #xD; pathologicalN 0..1 string Pathological N (pN) #xD; pathologicalM 0..1 string Pathological M (pM) #xD; postNeoadjuvantT 0..1 string Post-neoadjuvant pathological T (ypT) #xD; postNeoadjuvantN 0..1 string Post-neoadjuvant pathological N (ypN) #xD; postNeoadjuvantM 0..1 string Post-neoadjuvant pathological M (ypM) #xD; otherClassification 0..1 code Other classification Binding: BCR Other Stage Classification (required) #xD; otherStageGroup 0..1 string Other classification — stage #xD; clinicalTrialParticipation 0..1 code Clinical trial participation Binding: BCR Clinical Trial Indicator (required) #xD; eudraCtNumber 0..1 string EudraCT number #xD; treatmentEpisode 0..* BackboneElement Treatment chronology row #xD; <a href="StructureDefinition-bcr-cancer-registration-form-definitions.html#bcr-cancer-registration-form.treatmentEpisode.code" title="Chronology code. Codes:#xA;5 = diagnosis; 10 = surgery; 11 = excision biopsy;#xA;16 = HSCT autologous; 17 = HSCT allogeneic;#xA;20 = external radiotherapy / brachytherapy; 21 = IORT; 22 = hadron therapy;#xA;25 = concurrent chemoradiotherapy; 26 = concurrent radio-immunotherapy;#xA;30 = radio-isotopes; 35 = phototherapy; 36 = topical therapy;#xA;40 = chemotherapy / systemic therapy; 45 = targeted therapy (not 26, 60);#xA;50 = hormonal therapy; 60 = immunotherapy (not 26, 66);#xA;66 = concurrent chemo-immunotherapy;#xA;70 = symptomatic / palliative; 75 = active surveillance / watchful waiting;#xA;80 = other treatment (free-text comment required);#xA;90 = no therapy; 95 = treatment refusal; 99 = unknown.">code 1..1 code Diagnosis / treatment code Binding: BCR Treatment Chronology Code (required) #xD; campusId 0..1 string Campus / vestigingsnummer #xD; startDate 1..1 date Start date #xD; endDate 0..1 date End date #xD; comment 0..1 string Comment #xD; mocReport 0..* Attachment Attached MOC report(s) #xD; Documentation for this format
BCR Cancer Registration Form — Bijlage 55 (Logical Model)
Logical model of the Belgian standard cancer registration form (*Kankerregistratieformulier voor een nieuwe diagnose*). This is what hospitals submit to the Belgian Cancer Registry through WBCR or via batch extraction for every new cancer diagnosis. Distinct from `BCRCancerCase`, which models the *published research dataset* derived from these submissions plus registry follow-up. Source (canonical): Bijlage 55 to the RIZIV Verordening of 28 July 2003, as amended by the Verordening of 15 December 2025 (Belgisch Staatsblad 23-12-2025, p. 96356).
Free-text patient name as entered on the form.
Belgian national number (INSZ/NISS) or, when unavailable, the insurance fund number.
Date of incidence (DD-MM-YYYY) per ENCR/IACR international guidelines.
Most reliable method by which the diagnosis was established. Codes: 2 = histology of primary tumour, 3 = histology of metastasis, 4 = cytology / haematology, 5 = technical investigation (RX, endoscopy, …), 6 = clinical, 7 = tumour marker (PSA, hCG, AFP, Ig, …), 8 = cytogenetic / molecular tests, 9 = unknown.
Score at incidence date. Codes: 0 = asymptomatic, normal activity; 1 = symptomatic but ambulatory; 2 = symptomatic, bedridden <50% per day; 3 = symptomatic, bedridden >50% per day; 4 = fully dependent, 100% bedridden.
ICD-O-3 topography of the primary tumour.
Laterality of the primary tumour. Codes: 1 = left, 2 = right, 3 = unpaired organ, NK = unknown.
ICD-O-3 morphology code (the part before the slash on the form).
ICD-O-3 behaviour code (the part after the slash on the form: benign / borderline / in situ / malignant primary / malignant metastatic / unknown).
Grade of differentiation. Codes: 1 = well, 2 = moderate, 3 = poor, 4 = undifferentiated / anaplastic, 5 = T-cell, 6 = B-cell, 7 = null-cell (not T / not B), 8 = NK cell, 9 = unknown.
Pathological T after neoadjuvant therapy.
Pathological N after neoadjuvant therapy.
Pathological M after neoadjuvant therapy.
Alternative staging classification used when applicable. Codes: 1 = Childhood Cancer Stage, 2 = FIGO, 3 = Lugano, 4 = Breslow (in mm), 5 = other.
Stage value within the chosen alternative classification (e.g. Breslow depth in mm, FIGO stage).
Whether the cancer treatment is part of a clinical study (Ja / Nee / Onbekend).
EudraCT identifier of the trial when clinical trial participation is *Ja*.
One row of the chronology table, filled in chronologically from incidence date and first treatment.
All FHIR elements must have a @value or children
hasValue() or (children().count() > id.count())
Unique id for the element within a resource (for internal references). This may be any string value that does not contain spaces.
Extensions are always sliced by (at least) url
Additional content defined by implementations
May be used to represent additional information that is not part of the basic definition of the element. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension.
There can be no stigma associated with the use of extensions by any application, project, or standard - regardless of the institution or jurisdiction that uses or defines the extensions. The use of extensions is what allows the FHIR specification to retain a core level of simplicity for everyone.
Must have either extensions or value[x], not both
exists(f:extension)!=exists(f:*[starts-with(local-name(.), "value")])
Extensions that cannot be ignored even if unrecognized
May be used to represent additional information that is not part of the basic definition of the element and that modifies the understanding of the element in which it is contained and/or the understanding of the containing element's descendants. Usually modifier elements provide negation or qualification. To make the use of extensions safe and manageable, there is a strict set of governance applied to the definition and use of extensions. Though any implementer can define an extension, there is a set of requirements that SHALL be met as part of the definition of the extension. Applications processing a resource are required to check for modifier extensions. Modifier extensions SHALL NOT change the meaning of any elements on Resource or DomainResource (including cannot change the meaning of modifierExtension itself).
Modifier extensions allow for extensions that *cannot* be safely ignored to be clearly distinguished from the vast majority of extensions which can be safely ignored. This promotes interoperability by eliminating the need for implementers to prohibit the presence of extensions. For further information, see the [definition of modifier extensions](http://hl7.org/fhir/R4/extensibility.html#modifierExtension).
Modifier extensions are expected to modify the meaning or interpretation of the element that contains them
Chronology code. Codes: 5 = diagnosis; 10 = surgery; 11 = excision biopsy; 16 = HSCT autologous; 17 = HSCT allogeneic; 20 = external radiotherapy / brachytherapy; 21 = IORT; 22 = hadron therapy; 25 = concurrent chemoradiotherapy; 26 = concurrent radio-immunotherapy; 30 = radio-isotopes; 35 = phototherapy; 36 = topical therapy; 40 = chemotherapy / systemic therapy; 45 = targeted therapy (not 26, 60); 50 = hormonal therapy; 60 = immunotherapy (not 26, 66); 66 = concurrent chemo-immunotherapy; 70 = symptomatic / palliative; 75 = active surveillance / watchful waiting; 80 = other treatment (free-text comment required); 90 = no therapy; 95 = treatment refusal; 99 = unknown.
Hospital site identifier where the episode took place.
Free-text comment, required only for code 80 (other treatment).
MOC report(s) attached to the form. Only required for breast tumours per footnote 7 of Bijlage 55.